Tag: investor

MINNEAPOLIS, June 25, 2025 (GLOBE NEWSWIRE) -- Jefferson Capital, Inc. (“Jefferson Capital”), a leading analytically driven purchaser and manager of charged-off and insolvency consumer accounts, today announced the pricing of its underwritten initial public offering of 10,000,000 shares of common stock at an initial public offering price of $15.00 per share. Jefferson Capital is offering 625,000 shares of common stock, and certain existing stockholders are offering 9,375,000 shares of common stock. In addition, the underwriters of the offering have a 30-day option to purchase from the selling stockholders up to 1,500,000 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions. Jefferson Capital will not receive any proceeds from the sale of shares by the selling stockholders.

SAN DIEGO, June 25, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, inclusive (the “Class Period”), have until August 25, 2025 to seek appointment as lead plaintiff of the Hims & Hers class action lawsuit. Captioned Sookdeo v. Hims & Hers Health, Inc., No. 25-cv-05315 (N.D. Cal.), the Hims & Hers class action lawsuit charges Hims & Hers and certain of Hims & Hers’ top executives with violations of the Securities Exchange Act of 1934. A subsequently filed complaint is captioned Yaghsizian v. Hims & Hers Health, Inc., No. 25-cv-05321 (N.D. Cal.).

SAN FRANCISCO, June 25, 2025 (GLOBE NEWSWIRE) -- Biotechnology firm Iovance Biotherapeutics Inc. (NASDAQ: IOVA) announced a significant leadership transition, confirming the resignation of Chief Financial Officer Jean-Marc Bellemin, effective July 10, 2025. Mr. Bellemin, who assumed the CFO role in November 2020, is reportedly departing to pursue other endeavors, according to a regulatory filing. Bellemin’s exit comes at a tumultuous time, as the company is grappling with a recent commercial setback for its flagship drug, Amtagvi, and the specter of a class-action securities lawsuit.

SAN FRANCISCO, June 25, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit styled Ho v. Rocket Pharmaceuticals, Inc., et al., No. 3:25-cv-10049 (D. N.J.) has been filed and seeks to represent investors who purchased or otherwise acquired Rocket Pharmaceuticals securities between February 27, 2025 and May 26, 2025.

Company to host Investor Webcast on Thursday, June 26, 2025, at 8:30 am E.T.

NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Organon & Co. (NYSE: OGN) between October 31, 2024 and April 30, 2025, both dates inclusive (the “Class Period”), of the important July 22, 2025 lead plaintiff deadline.

LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL re-launched and commercial sales ongoing  

VANCOUVER, British Columbia, June 25, 2025 (GLOBE NEWSWIRE) -- Hapbee Technologies, Inc. (TSXV: HAPB) (OTCQB: HAPBF) (FSE: HA1) (“Hapbee” or the “Company”), the digital wellness technology company, is pleased to announce a non-brokered private placement consisting of up to 15,070,000 units (“Units”) at a price of $0.10 per Unit for aggregate gross proceeds of up to $1,507,000 (the “Offering”). Each Unit will consist of one subordinate voting common share of the Company (a “Share”) and one-half of one common share purchase warrant (each whole warrant, a “Warrant”). Each Warrant will be exercisable for one additional Share of the Company at a price of $0.20 CAD for two years from the date of issuance.

TORONTO, June 25, 2025 (GLOBE NEWSWIRE) -- Clairvest Group Inc. (TSX: CVG) today reported results for the fourth quarter and year ended March 31, 2025 and events which occurred subsequent to year end. (All figures are in Canadian dollars unless otherwise stated)